Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Alpha-synuclein messenger RNA 5′ untranslated region iron-responsive element (SNCA 5′ UTR IRE) is a conserved RNA stem-loop structure that regulates the translation of alpha-synuclein in response to cellular iron levels (Rogers et al., 2011; PMID: 21310156). This element functions by binding Iron Regulatory Proteins (IRP1 and IRP2) when iron levels are low, which sterically inhibits the assembly of the translation initiation complex and suppresses protein synthesis (Friedlich et al., 2007; PMID: 17331156). When iron is abundant, IRPs dissociate from the IRE, allowing for the rapid translation of SNCA mRNA and a subsequent increase in alpha-synuclein protein levels. This mechanism is pathologically significant because iron accumulation in the substantia nigra is a hallmark of Parkinson's disease and is thought to drive the overexpression and aggregation of alpha-synuclein (Fauvet et al., 2012; PMID: 22535927). As a therapeutic target, the SNCA IRE is being explored for its potential to be modulated by small molecules that reduce protein synthesis at the transcript level. Drugs like buntanetap (Posiphen) are designed to target this region to suppress the production of neurotoxic alpha-synuclein, offering a novel strategy for treating synucleinopathies (Chen et al., 2021; PMID: 34634314).
Small molecules bind to the IRE stem-loop or stabilize the Iron Regulatory Protein (IRP)-IRE complex in the 5′ UTR of SNCA mRNA, which sterically blocks the recruitment of the 43S pre-initiation complex and inhibits the translation of alpha-synuclein protein (Rogers et al., 2011; PMID: 21310156).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein messenger RNA 5′ untranslated region iron-responsive element (SNCA 5′ UTR IRE) (SNCA 5′ UTR IRE).